Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Reports Strong Q1 2026 Financial Results and Strategic Collaborations
Summary
Alnylam Pharmaceuticals, Inc. reported its first quarter 2026 financial results, achieving global net product revenues of $1,036 million, a 121% growth compared to Q1 2025. The company's TTR franchise, particularly AMVUTTRA, drove this growth with total TTR revenues of $910 million, a 153% increase year-over-year. Alnylam reiterated its 2026 financial guidance, expecting combined net product revenues between $4,900 million and $5,300 million. Additionally, the company announced new strategic collaborations with Viz.ai and the American Heart Association aimed at improving diagnosis and care for ATTR-CM patients.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement